Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Cash from Operations of $136.4 million for Q2 2026, up 33.7% from $102 million a year earlier but down 6.4% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Cash from Operations at Neurocrine Biosciences was $898.1 million, up 58.3% year-over-year; for FY2025, it came in at $782.7 million, up 31.5% from FY2024.
- Annual Cash from Operations has increased for seven consecutive years, with a five-year compound annual growth rate of 27.9% (FY2020 to FY2025).
- In prior years, Neurocrine Biosciences' Cash from Operations was $595.4 million in FY2024 (+52.7%), $389.9 million in FY2023 (+14.9%), $339.4 million in FY2022 (+32.3%) and $256.5 million in FY2021 (+12.3%).
- Quarterly Cash from Operations has run from a low of -$125.2 million in Q1 2023 to a high of $388.4 million in Q4 2025 over five years.
- On a year-over-year basis, Cash from Operations has increased in each of the last five quarters, with growth averaging 42.7% over the last eight quarters.
- The strongest year-over-year quarter for Cash from Operations in the past five years was Q1 2026, with growth of 125.0%; the weakest was Q4 2021, with a decline of 95.6%.
- According to Business Quant data, Cash from Operations for the three prior quarters was $145.8 million (Q1 2026), $388.4 million (Q4 2025) and $227.5 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 4.58 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.13 Bn |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 136.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 136.40 Mn |
| Mar 31, 2026 | 145.80 Mn |
| Dec 31, 2025 | 388.40 Mn |
| Sep 30, 2025 | 227.50 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Mar 31, 2025 | 64.80 Mn |
| Dec 31, 2024 | 242.50 Mn |
| Sep 30, 2024 | 158.00 Mn |
| Jun 30, 2024 | 64.60 Mn |
| Mar 31, 2024 | 130.30 Mn |
| Dec 31, 2023 | 123.50 Mn |
| Sep 30, 2023 | 212.00 Mn |
| Jun 30, 2023 | 179.60 Mn |
| Mar 31, 2023 | -125.20 Mn |
| Dec 31, 2022 | 143.00 Mn |
| Sep 30, 2022 | 98.80 Mn |
| Jun 30, 2022 | 138.10 Mn |
| Mar 31, 2022 | -40.50 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Sep 30, 2021 | 61.80 Mn |
API Access
Neurocrine Biosciences Cash from Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-operations&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-operations", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-operations&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();